EBMT 2024 | Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig, MD, MSc, University Hospital TU Dresden, Dresden, Germany, discusses the ASAP trial (NCT02461537), which aimed to demonstrate the benefit of achieving a complete remission (CR) with intense chemotherapy prior to allogeneic stem cell transplantation (alloSCT) in relapsed acute myeloid leukemia (AML). Chemotherapy with high-dose cytarabine and mitoxantrone before alloSCT did not result in a higher overall success rate and did not confer a survival advantage. This poses the possibility to proceed to alloSCT immediately without a need to induce CR. Dr Schetelig also discusses the impact of measurable residual disease (MRD) on alloSCT outcomes. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Boards organized by Abbvie, AstraZeneca, BeiGene, BMS, Janssen, and MSD.
Lecture Fees from Astellas, AstraZeneca, BeiGene, BMS, Novartis, Eurocept , Medac and Janssen.
